{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:56:04Z","timestamp":1791276964412,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000595","name":"DARWIN","doi-asserted-by":"publisher","award":["EUPAS1000000430"],"award-info":[{"award-number":["EUPAS1000000430"]}],"id":[{"id":"10.13039\/501100000595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. However, large-scale epidemiological evidence remains scarce due to challenges in real-world disease recognition. This study aimed to characterize clinically recognized HCM and obstructive HCM (oHCM) across six European countries regarding prevalence, demographics, and clinical characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using routinely collected healthcare data from six European countries, all mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model within the DARWIN EU\u00ae network: CPRD-GOLD (UK), DK-DHR (Denmark), InGef RDB (Germany), NAJS (Croatia), NLHR (Norway), and SIDIAP (Spain). Clinically recognized HCM was defined based on recorded diagnoses captured in routine healthcare data, rather than on imaging-, haemodynamic-, or genotype-confirmed population screening. Adults (\u226518 years) with a first recorded HCM or oHCM diagnosis after 2010 were included. We estimated annual period prevalence and described recorded comorbidities, diagnostic measurements, and treatments before, at, and after diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 40 277 individuals with HCM, 12 363 (31%) were first diagnosed with oHCM. Females were older than males at diagnosis (median 67\u201378 vs 57\u201368 years). Annual period prevalence increased over time, ranging from 0.04% (95% Confidence interval: 0.04\u20130.05) to 0.24% (0.23\u20130.24) in recent years. Prevalence was higher in males, but differences diminished among those aged \u226580 and with oHCM. Cardiovascular comorbidities were frequently recorded before and at the time of first diagnosis, especially hypertension, cardiac arrhythmias, ischaemic heart disease, and heart failure. Beta-blockers, diuretics, and angiotensin-converting enzyme inhibitors were the most common treatments. Most comorbidities and treatments were recorded over a year before HCM diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An increase in the prevalence of clinically recognized HCM across Europe was observed over time. This trend is likely multifactorial and may reflect changes in disease recognition, clinical practice, demographics, database-related factors, and potentially the underlying disease burden. Cardiovascular comorbidities and treatments were frequently recorded prior to diagnosis, which may suggest that some patients would benefit from increased diagnostic awareness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag218","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:39:45Z","timestamp":1787053185000},"source":"Crossref","is-referenced-by-count":0,"title":["Characterizing clinically recognized hypertrophic cardiomyopathy in six European countries using real-world data"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4405-1814","authenticated-orcid":false,"given":"Marta","family":"Alcalde-Herraiz","sequence":"first","affiliation":[{"name":"Health Data Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford , OX3 7LD Oxford ,","place":["England"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Delmestri","sequence":"additional","affiliation":[{"name":"Health Data Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford , OX3 7LD Oxford ,","place":["England"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hezekiah","family":"Omulo","sequence":"additional","affiliation":[{"name":"Health Data Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford , OX3 7LD Oxford ,","place":["England"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Br\u00e4uner","sequence":"additional","affiliation":[{"name":"Data Analytics Center, Danish Medicines Agency , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Bruun","sequence":"additional","affiliation":[{"name":"Data Analytics Center, Danish Medicines Agency , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raeleesha","family":"Norris","sequence":"additional","affiliation":[{"name":"InGef\u2014Institute for Applied Health Research Berlin GmbH Data Science\/Health Services Research, , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Vivirito","sequence":"additional","affiliation":[{"name":"InGef\u2014Institute for Applied Health Research Berlin GmbH Data Science\/Health Services Research, , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Harms","sequence":"additional","affiliation":[{"name":"InGef\u2014Institute for Applied Health Research Berlin GmbH Data Science\/Health Services Research, , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakov","family":"Vukovi\u0107","sequence":"additional","affiliation":[{"name":"Croatian National Institute of Public Health Medical Informatics and Biostatistics Division, , Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Prista\u0161","sequence":"additional","affiliation":[{"name":"Croatian National Institute of Public Health Medical Informatics and Biostatistics Division, , Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamaria","family":"Jur\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Croatian National Institute of Public Health Medical Informatics and Biostatistics Division, , Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"\u010cavlina","sequence":"additional","affiliation":[{"name":"Croatian National Institute of Public Health Medical Informatics and Biostatistics Division, , Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antea","family":"Jezid\u017ei\u0107","sequence":"additional","affiliation":[{"name":"Croatian National Institute of Public Health Medical Informatics and Biostatistics Division, , Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pero","family":"Ivanko","sequence":"additional","affiliation":[{"name":"Croatian National Institute of Public Health Medical Informatics and Biostatistics Division, , Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Hayati","sequence":"additional","affiliation":[{"name":"PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhung T H","family":"Trinh","sequence":"additional","affiliation":[{"name":"PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig Marie Egeland","family":"Nordeng","sequence":"additional","affiliation":[{"name":"PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Department of Child Health and Development, Norwegian Institute of Public Health , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talita","family":"Duarte-Salles","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Institut Universitari Per a la Recerca a l'Atenci\u00f3 Prim\u00e0ria de Salut Jordi Gol i Gurina (IDIAPJGol) Unitat Transversal de Recerca (UTR), , Barcelona ,","place":["Spain"]},{"name":"Department of Medical Informatics, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Palomar-Cros","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Institut Universitari Per a la Recerca a l'Atenci\u00f3 Prim\u00e0ria de Salut Jordi Gol i Gurina (IDIAPJGol) Unitat Transversal de Recerca (UTR), , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Giuliodori","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Institut Universitari Per a la Recerca a l'Atenci\u00f3 Prim\u00e0ria de Salut Jordi Gol i Gurina (IDIAPJGol) Unitat Transversal de Recerca (UTR), , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"G\u00f3mez-Outes","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Clinical Drug Evaluation, Medicines for Human Use, Spanish Agency for Medicines and Healthcare Products (AEMPS) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vrijlandt","sequence":"additional","affiliation":[{"name":"Dutch Medicines Evaluation Board , Utrecht ,","place":["The Netherlands"]},{"name":"Deparment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Clara","family":"Restrepo-M\u00e9ndez","sequence":"additional","affiliation":[{"name":"European Medicines Agency , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-1128","authenticated-orcid":false,"given":"Edward","family":"Burn","sequence":"additional","affiliation":[{"name":"Health Data Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford , OX3 7LD Oxford ,","place":["England"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-9153","authenticated-orcid":false,"given":"Albert","family":"Prats-Uribe","sequence":"additional","affiliation":[{"name":"Health Data Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford , OX3 7LD Oxford ,","place":["England"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Saura-L\u00e1zaro","sequence":"additional","affiliation":[{"name":"Health Data Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford , OX3 7LD Oxford ,","place":["England"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026100604480890600_xvag218-B1","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Authors\/Task Force members","year":"2014","journal-title":"Eur Heart J"},{"key":"2026100604480890600_xvag218-B2","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1161\/CIR.0000000000000937","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"2026100604480890600_xvag218-B3","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.1161\/CIR.0000000000000945","article-title":"Correction to: 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"142","year":"2020","journal-title":"Circulation"},{"key":"2026100604480890600_xvag218-B4","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/S0140-6736(13)60922-8","article-title":"Hypertrophic cardiomyopathy - authors\u2019 reply","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"2026100604480890600_xvag218-B5","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1056\/NEJMc1812159","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"2026100604480890600_xvag218-B6","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"2026100604480890600_xvag218-B7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.15420\/ecr.2017:12:1","article-title":"Hypertrophic cardiomyopathy in athletes","volume":"12","author":"Malhotra","year":"2017","journal-title":"Eur Cardiol"},{"key":"2026100604480890600_xvag218-B8","author":"Food and Drug Administration (FDA)"},{"key":"2026100604480890600_xvag218-B9","author":"Bristol Myers Squibb"},{"key":"2026100604480890600_xvag218-B10","author":"European Medicines Agency (EMA)"},{"key":"2026100604480890600_xvag218-B11","author":"European Medicines Agency (EMA)"},{"key":"2026100604480890600_xvag218-B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-074010","article-title":"Temporal trends of hypertrophic cardiomyopathy in Denmark: a nationwide retrospective cohort study","volume":"13","author":"Zorner","year":"2023","journal-title":"BMJ Open"},{"key":"2026100604480890600_xvag218-B13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/pds.5507","article-title":"HARmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE\/ISPOR task force","volume":"32","author":"Wang","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026100604480890600_xvag218-B14","author":"European Medicines Agency (EMA)"},{"key":"2026100604480890600_xvag218-B15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.farma.2025.02.011","article-title":"Real-world evidence for regulatory purposes: the example of DARWIN EU(R)","volume":"49","author":"Raventos","year":"2025","journal-title":"Farm Hosp"},{"key":"2026100604480890600_xvag218-B16","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70042","article-title":"Standardised and reproducible phenotyping using distributed analytics and tools in the Data Analysis and Real World Interrogation Network (DARWIN EU)","volume":"33","author":"Dernie","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026100604480890600_xvag218-B17","author":"National Cancer Institute (NCI)"},{"key":"2026100604480890600_xvag218-B18","author":"Wickham"},{"key":"2026100604480890600_xvag218-B19","author":"Black"},{"key":"2026100604480890600_xvag218-B20","author":"Burn"},{"key":"2026100604480890600_xvag218-B21","author":"Burn"},{"key":"2026100604480890600_xvag218-B22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5717","article-title":"Incidence Prevalence: an R package to calculate population-level incidence rates and prevalence using the OMOP common data model","volume":"33","author":"Raventos","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026100604480890600_xvag218-B23","author":"Catala"},{"key":"2026100604480890600_xvag218-B24","author":"Catal\u00e0"},{"key":"2026100604480890600_xvag218-B25","author":"European Medicines Agency (EMA)"},{"key":"2026100604480890600_xvag218-B26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"2026100604480890600_xvag218-B27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijcard.2023.04.005","article-title":"How common is hypertrophic cardiomyopathy \u2026 really?: disease prevalence revisited 27 years after CARDIA","volume":"382","author":"Massera","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026100604480890600_xvag218-B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196612","article-title":"Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany\u2014an analysis of over 5 million patients","volume":"13","author":"Husser","year":"2018","journal-title":"PLoS One"},{"key":"2026100604480890600_xvag218-B29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/CLEP.S139300","article-title":"Misclassification of hypertrophic cardiomyopathy: validation of diagnostic codes","volume":"9","author":"Magnusson","year":"2017","journal-title":"Clin Epidemiol"},{"key":"2026100604480890600_xvag218-B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191214","article-title":"Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records","volume":"13","author":"Pujades-Rodriguez","year":"2018","journal-title":"PLoS One"},{"key":"2026100604480890600_xvag218-B31","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1001\/jamacardio.2021.0689","article-title":"Prevalence of hypertrophic cardiomyopathy in the UK biobank population","volume":"6","author":"Lopes","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026100604480890600_xvag218-B32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012250","article-title":"Prevalence of unexplained left ventricular hypertrophy by cardiac magnetic resonance imaging in MESA","volume":"8","author":"Massera","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026100604480890600_xvag218-B33","doi-asserted-by":"publisher","first-page":"18799","DOI":"10.1038\/s41598-022-20042-9","article-title":"Prevalence, incidence and mortality of hypertrophic cardiomyopathy based on a population cohort of 21.9 million in China","volume":"12","author":"Bai","year":"2022","journal-title":"Sci Rep"},{"key":"2026100604480890600_xvag218-B34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.amjcard.2021.08.024","article-title":"Clinical diagnosis of hypertrophic cardiomyopathy over time in the United States (A population-based claims analysis)","volume":"159","author":"Butzner","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026100604480890600_xvag218-B35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jjcc.2010.07.004","article-title":"Gender-specific differences in the clinical features of hypertrophic cardiomyopathy in a community-based Japanese population: results from Kochi RYOMA study","volume":"56","author":"Kubo","year":"2010","journal-title":"J Cardiol"},{"key":"2026100604480890600_xvag218-B36","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jacc.2005.04.043","article-title":"Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy","volume":"46","author":"Olivotto","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026100604480890600_xvag218-B37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007230","article-title":"Temporal trend of age at diagnosis in hypertrophic cardiomyopathy: an analysis of the international sarcomeric human cardiomyopathy registry","volume":"13","author":"Canepa","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026100604480890600_xvag218-B38","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.amjcard.2004.03.007","article-title":"Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the strong heart study)","volume":"93","author":"Maron","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026100604480890600_xvag218-B39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11897-021-00526-x","article-title":"Sex differences in hypertrophic cardiomyopathy: interaction with genetics and environment","volume":"18","author":"Butters","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"2026100604480890600_xvag218-B40","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/eurheartj\/ehx527","article-title":"Women with hypertrophic cardiomyopathy have worse survival","volume":"38","author":"Geske","year":"2017","journal-title":"Eur Heart J"},{"key":"2026100604480890600_xvag218-B41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev-med-042220-021539","article-title":"Hypertrophic cardiomyopathy: new concepts and therapies","volume":"73","author":"Maron","year":"2022","journal-title":"Annu Rev Med"},{"key":"2026100604480890600_xvag218-B42","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014448","article-title":"Sex, survival, and cardiomyopathy: differences between men and women with hypertrophic cardiomyopathy","volume":"8","author":"Siontis","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026100604480890600_xvag218-B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227012","article-title":"Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: a nationwide population-based cohort study","volume":"15","author":"Moon","year":"2020","journal-title":"PLoS One"},{"key":"2026100604480890600_xvag218-B44","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026100604480890600_xvag218-B45","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1136\/heartjnl-2021-320181","article-title":"Epidemiology of cardiomyopathies and incident heart failure in a population-based cohort study","volume":"108","author":"Brownrigg","year":"2022","journal-title":"Heart"},{"key":"2026100604480890600_xvag218-B46","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0735-1097(03)00855-6","article-title":"Clinical course of hypertrophic cardiomyopathy with survival to advanced age","volume":"42","author":"Maron","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026100604480890600_xvag218-B47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.116.001620","article-title":"Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications","volume":"10","author":"Ingles","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"2026100604480890600_xvag218-B48","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.rec.2017.06.002","article-title":"Factors influencing the phenotypic expression of hypertrophic cardiomyopathy in genetic carriers","volume":"71","author":"Perez-Sanchez","year":"2018","journal-title":"Rev Esp Cardiol (Engl Ed)"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag218\/70721110\/xvag218.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag218\/70721110\/xvag218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag218\/70721110\/xvag218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:48:16Z","timestamp":1791276496000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag218\/8766945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,8,20]]},"published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag218","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,20]]},"article-number":"xvag218"}}